600216 浙江醫藥
按盤價 
17.300 -0.390 (-2.205%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 6,695,298 | -5.87% | 9,375,217 | 7,794,146 | 8,115,805 | 9,129,094 | |
| 減：營業總成本 | 5,638,082 | -7.62% | 7,934,024 | 7,681,666 | 7,482,025 | 7,932,301 | |
| 其中:營業成本 | 4,184,975 | -1.85% | 5,406,541 | 5,269,879 | 5,318,274 | 5,399,736 | |
| 財務費用 | (93,264) | 3,150.21% | (4,958) | (17,488) | (37,966) | 93,110 | |
| 資產減值損失 | (94,216) | -7.17% | (263,899) | (137,208) | (117,141) | (165,169) | |
| 公允價值變動收益 | 21,365 | -697.08% | (21,534) | (10,099) | (23,881) | 51,726 | |
| 投資收益 | 5,365 | -133.08% | (8,069) | (3,505) | (32,626) | 41,815 | |
| 其中：對聯營企業和合營企業的投資收益 | (6,736) | -45.51% | (9,643) | (9,782) | (3,806) | (4,240) | |
| 營業利潤 | 1,048,294 | 11.87% | 1,223,110 | 380,158 | 504,616 | 1,179,437 | |
| 利潤總額 | 1,046,307 | 12.41% | 1,212,282 | 363,279 | 491,388 | 1,153,532 | |
| 減：所得稅費用 | 179,575 | 4.25% | 192,031 | 86,485 | 128,775 | 268,972 | |
| 淨利潤 | 866,732 | 14.26% | 1,020,252 | 276,794 | 362,614 | 884,559 | |
| 減：非控股權益 | (66,416) | -27.09% | (140,259) | (152,845) | (176,956) | (160,763) | |
| 股東淨利潤 | 933,148 | 9.83% | 1,160,511 | 429,640 | 539,570 | 1,045,322 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.970 | 10.23% | 1.210 | 0.450 | 0.560 | 1.090 | |
| 每股派息 (元) * | -- | -- | 0.370 | 0.150 | 0.170 | 0.330 | |
| 每股淨資產 (元) * | 11.496 | 6.90% | 11.073 | 9.980 | 9.594 | 9.096 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 12/03/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
